Hyrimoz kit is a prescription medicine containing Adalimumab, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
HYRIMOZ must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE…
Key facts
- Active ingredient (INN)
- Adalimumab
- Brand
- Hyrimoz
- Dosage form
- Kit
- Packs
- 3 kits, 2 kits, 1 kit
- Marketing authorisation holder
- Sandoz
- Manufacturers
- SandozCordavis
- Origin register
- US FDA, United States
- Storage
- HYRIMOZ must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. HYRIMOZ single-dose prefilled syringe with BD UltraSafe Passive™ Needle Guard (20 mg/0.4 mL, 40 mg/0.8 mL) and HYRIMOZ single-dose prefilled Sensoready Pen (40 mg/0.8 mL): If needed, for example when traveling, HYRIMOZ may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 21 days, with…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AB04 Adalimumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 2023
- Identifiers
- RxCUI 2641644, 2641650, 2641653 +7DailyMed set ID 1ac7d061-3380-468c-b077-c05f8dfbc829, 3e303a4a-980b-4f2a-9d03-786928758637NDC 61314-531, 61314-517, 83457-112Application BLA761071
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 kit in 1 carton / 1 kit in 1 kit * 1 syringe in 1 carton / .8 mL in 1 syringe * 2 carton in 1 carton / 1 syringe in 1 carton / .4 mL in 1 syringe | 61314-517-36 | Sandoz | 1 July 2023 |
| 2 kit in 1 carton / 1 kit in 1 kit * 1 syringe, glass in 1 carton / .8 mL in 1 syringe, glass * 1 syringe, glass in 1 carton / .4 mL in 1 syringe, glass | 61314-531-64 | Sandoz | 1 July 2023 |
| 1 kit in 1 carton * 2 syringe in 1 carton / .4 mL in 1 syringe * 1 syringe in 1 carton / .8 mL in 1 syringe | 83457-112-01 | Cordavis | 15 December 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Adalimumab kit.
- Adalimumab kitAvailable on request—US FDA36 packs Cold chain
- Humira kitAvailable on requestAbbVieUS FDA19 packs Cold chain
- Abrilada kitAvailable on requestPfizer LaboratoriesUS FDA6 packs Cold chain
- Adalimumab kitAvailable on request—US FDA6 packs Cold chain
- Cyltezo kitAvailable on requestBoehringer Ingelheim PharmaceuticalsUS FDA6 packs Cold chain
- Simlandi kitAvailable on requestTeva PharmaceuticalsUS FDA4 packs Cold chain
Other strengths and forms of Adalimumab
Clinical summary
Adalimumab is a tumor necrosis factor blocker indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. MedsAcross supplies Adalimumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AdalimumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Humira prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Humira: European public assessment report (EPAR) · European Medicines Agency
- Amgevita: European public assessment report (EPAR) · European Medicines Agency
Need Hyrimoz kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.